Is Autolus Therapeutics plc (NASDAQ:AUTL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Autolus Therapeutics plc at current levels.
AUCATZYL is the first truly commercial-grade CAR-T for adult ALL, and the market is pricing it like another biotech zombie.
Where AUTL is headed
Autolus walked into 2026 with a drug that actually works in a cancer where almost nothing does. AUCATZYL, approved in late 2024 for adult relapsed/refractory B-ALL, is doing something no previous CD19 CAR-T has pulled off: deep, durable remissions without the Grade 3+ cytokine release storms that make Yescarta and Kymriah a hospital-ward ordeal. The clinical profile matters commercially, because it means community oncology centers can realistically administer it rather than funneling every patient to a handful of academic hubs. By late 2027, if the US launch tracks even conservatively against the roughly 1,000 eligible US patients per year at a $525k list price, you are looking at a product doing $250M to $400M annualized in its lead indication alone, with EU and UK revenue stacking on top through 2028.
Read the full Compass Direction on AUTL
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $1.77).
See the full AUTL analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Autolus Therapeutics plc (NASDAQ:AUTL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Autolus Therapeutics plc at current levels. AUCATZYL is the first truly commercial-grade CAR-T for adult ALL, and the market is pricing it like another biotech zombie.
What is AUTL's Compass Score?
Autolus Therapeutics plc scores 70/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for AUTL?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the AUTL page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.